Higher margins but lower sales growth in Q4. -2% EBITDA revisions, more on EPS due to tax. BUY case and TP of SEK 23 unchanged.

22 Feb 2024
BUY case intact despite miss on sales growth

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BUY case intact despite miss on sales growth
- Published:
22 Feb 2024 -
Author:
ABGSC Healthcare Research | Sten Gustafsson -
Pages:
14 -
Higher margins but lower sales growth in Q4. -2% EBITDA revisions, more on EPS due to tax. BUY case and TP of SEK 23 unchanged.